Supernus Pharmaceuticals, Inc.

SUPN · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$74$1$61$53
Dep. & Amort.$80$85$86$33
Deferred Tax-$20-$26-$26-$5
Stock-Based Comp.$28$27$18$18
Change in WC-$2-$9-$24$4
Other Non-Cash$12$33$4$25
Operating Cash Flow$172$111$117$127
Investing Activities
PP&E Inv.-$1-$1-$0-$2
Net Acquisitions$0$0-$0-$312
Inv. Purchases-$688-$102-$407-$312
Inv. Sales/Matur.$499$371$191$531
Other Inv. Act.$0$0$0$13
Investing Cash Flow-$190$269-$217-$82
Financing Activities
Debt Repay.$0-$403$0-$138
Stock Issued$15$7$12$7
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$3-$2-$23$0
Financing Cash Flow$12-$398-$10-$130
Forex Effect$0$0$0$0
Net Chg. in Cash-$6-$18-$110-$85
Supplemental Information
Beg. Cash$75$93$203$289
End Cash$69$75$93$203
Free Cash Flow$171$111$116$125
Supernus Pharmaceuticals, Inc. (SUPN) Financial Statements & Key Stats | AlphaPilot